Integra Lifesciences Holdings Corp revenue by segment IART

Annual Quarterly

Integra Lifesciences Holdings Corp splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Specialty Surgery at $304.1 million, 74% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Neurosurgery at $214.1 million, 52% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	1,657	411	419	392	435	402	416	383	443
Operating segments
Specialty Surgery	1,220 +2.3% share 73.6%	304 +3.9% share 74.0%	309 +1.7% share 73.9%	283 +0.9% share 72.2%	323 +2.7% share 74.3%	293 share 72.8%	304 share 73.1%	281 share 73.3%	315 share 71.1%
Tissue Reconstruction	437 -3.1% share 26.4%	107 -2.2% share 26.0%	109 -1.9% share 26.1%	109 +6.7% share 27.8%	112 -12.8% share 25.7%	109 share 27.2%	112 share 26.9%	102 share 26.7%	128 share 28.9%
Sales mix
Neurosurgery	—	214 +6.2% share 52.1%	213 +2.0% share 50.9%	198 +3.8% share 50.6%	226 +2.8% share 52.0%	202 share 50.1%	209 share 50.3%	191 share 49.9%	220 share 49.7%
Wound Reconstruction Solutions	—	82 -2.9% share 19.8%	81 -4.1% share 19.4%	—	—	84 share 20.9%	85 share 20.4%	—	—
Surgical Instruments	—	50 -1.0% share 12.1%	55 +3.3% share 13.1%	—	—	50 share 12.5%	53 share 12.8%	—	—
ENT Solutions	—	40 -1.2% share 9.8%	41 -1.6% share 9.8%	—	—	41 share 10.2%	42 share 10.1%	—	—
Corporate Partnerships	—	26 +0.2% share 6.2%	—	—	—	25 share 6.3%	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: IART (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Princeton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 917520
Former names: INTEGRA LIFESCIENCES CORP (until Mar 31, 1999)

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.